Orbimed Advisors LLC Intercept Pharmaceuticals, Inc. Transaction History

Orbimed Advisors LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2020 May 15, 2020	SELL	$48.35 - $118.68 $1.1 Million - $2.71 Million	-22,800 Closed	0 $0
Q4 2019 Feb 14, 2020	SELL	$57.36 - $124.1 $539,184 - $1.17 Million	-9,400 Reduced 29.19%	22,800 $2.83 Million
Q3 2019 Nov 14, 2019	BUY	$58.69 - $80.46 $1.89 Million - $2.59 Million	32,200 New	32,200 $2.14 Million
Q1 2019 May 15, 2019	SELL	$91.83 - $120.68 $4.39 Million - $5.77 Million	-47,800 Closed	0 $0
Q4 2018 Feb 14, 2019	BUY	$85.79 - $126.46 $4.1 Million - $6.04 Million	47,800 New	47,800 $4.82 Million
Q4 2017 Feb 14, 2018	SELL	$58.2 - $72.76 $22.5 Million - $28.1 Million	-386,380 Closed	0 $0
Q3 2017 Nov 14, 2017	BUY	$57.01 - $118.75 $22 Million - $45.9 Million	386,380	386,380 $22.4 Million

1.04M

30K

5.9K

Ticker ICPT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 41,127,400
Description
Intercept Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat progressive non-viral liver diseases in the United States, Europe, and Canada. The company markets Ocaliva, a farnesoid X receptor agonist used for the treatment of primary biliary cholangitis in combination wit...

Get notified when there are updates to the investment portfolio of Orbimed Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Orbimed Advisors LLC with notifications on news.